You Position: Home > Paper
胰腺癌人源性肿瘤组织异种移植模型的现状与展望
( views:94, downloads:40 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Pancreatology
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1674-1935.2018.04.017
- Key Word:
- No keyword available
Abstract： 过去几十年间,胰腺癌常用的临床前模型是体外培养的肿瘤细胞或衍生于细胞的小鼠异种移植物,该模型存在长期离体培养引起生物学性质改变从而导致基因表达模式的改变[1]、体外培养的细胞缺失肿瘤微环境[2-5]、肿瘤细胞系传代培养不能反映不同患者之间的异质性等不足.人源性肿瘤组织异种移植(patient-derived tumor xenografts,PDTX)模型的出现弥补了上述不足.胰腺癌PDTX模型的建立是将新鲜的胰腺癌肿瘤组织移植到免疫缺陷鼠体内的过程,它保留了原发肿瘤的相似性,在相对真实的肿瘤基质微环境中生长、传代,高度保留了原始胰腺癌的异质性[6],这种相似性不仅表现在基因来源、组织结构、生物学行为上,更表现为对药物的反应具有很好的平行性和预测性.
- [1]Moore T,Amos KD,Ji B,etc.Cancer-associated stromal fibroblasts promote pancreatic tumor progression.[J].2008,68(3).
- [2]Dustin M, Walters,Jayme B, Stokes,Sara J, Adair,etc.Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens.[J].2013,8(10).
- [3]Xue, Aiqun,Julovi, Sohel M.,Hugh, Thomas J.,etc.A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas[J].2015,15(4).
- [4]I. Fichtner,W. Slisow,J. Gill,etc.Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas[J].2004,40(2).
- [5]Li, Jian-Ang,Xu, Xue-Feng,Han, Xu,etc.Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models[J].2016,45(3).
- [6]Weaver VM,Kumar S.Mechanics, malignancy, and metastasis: the force journey of a tumor cell.[J].2009,28(1).
- [7]R, Perez-Soler,B, Kemp,Q P, Wu,etc.Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.[J].2000,6(12).
- [8]Philip PA,Mooney M,Jaffe D,etc.Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.[J].2009,27(33).
- [9]Siolas,D.,Hannon,G.J..Patient-derived tumor xenografts: Transforming clinical samples into mouse models[J].2013,73(17).
- [10]Yano, S.,Hiroshima, Y.,Maawy, A.,etc.Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery[J].2015,22(7).
- [11]Robert J, Allaway,Dawn A, Fischer,Francine B, de Abreu,etc.Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.[J].2016.
- [12]Kerbel RS.Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.[J].2003,2(4 Suppl.).
- [13]Mattie,M.,Christensen,A.,Chang,M.S.,etc.Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics[J].2013,15(10).
- [14]Hruban RH,Hidalgo M,Rajeshkumar NV,etc.Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.[J].2011,10(1).
- [15]Parker NR,Phillips PA,Xu Z,etc.Pancreatic stellate cells: partners in crime with pancreatic cancer cells.[J].2008,68(7).
- [16]Salvador Navarro,Anna Vidal-Pla,Neus Carbó,etc.Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.[J].2011,34(6).
- [17]DePinho RA,Kimmelman AC,Chu GC,etc.Stromal biology of pancreatic cancer.[J].2007,101(4).
- [18]Hwang, Ho Kyoung,Kim, Hyoung-Il,Kim, Se Hoon,etc.Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3(+))/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer[J].2016,12(6 Pt.A).
- [19]Uson M,Salomon A,Hidalgo M,etc.Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.[J].2011,17(17).
- [20]John T,Kohler D,Yanagawa N,etc.The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.[J].2011,17(1).
- [21]B Rubio-Viqueira,M Hidalgo.Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients[J].2009,85(2).
- [22]Rubio Viqueira B,Jimeno A,Cusatis G,etc.An in vivo platform for translational drug development in pancreatic cancer.[J].2006,12(15).